The Manufacturers Life Insurance Company Sells 1,437 Shares of Immunome, Inc. (NASDAQ:IMNM)

The Manufacturers Life Insurance Company reduced its stake in Immunome, Inc. (NASDAQ:IMNM) by 0.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 165,491 shares of the company’s stock after selling 1,437 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.28% of Immunome worth $2,419,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of IMNM. Cerity Partners LLC increased its position in Immunome by 10.5% in the third quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock worth $776,000 after buying an additional 5,043 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Immunome by 217.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock worth $6,469,000 after acquiring an additional 302,916 shares in the last quarter. Primecap Management Co. CA raised its stake in Immunome by 4.5% during the 3rd quarter. Primecap Management Co. CA now owns 280,800 shares of the company’s stock worth $4,105,000 after acquiring an additional 12,000 shares during the period. Intech Investment Management LLC purchased a new position in Immunome during the third quarter valued at approximately $219,000. Finally, Victory Capital Management Inc. lifted its holdings in Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after purchasing an additional 237,497 shares in the last quarter. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Piper Sandler decreased their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Immunome in a report on Friday, October 25th. Finally, Stephens started coverage on Immunome in a research note on Friday, November 8th. They issued an “overweight” rating and a $30.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Immunome presently has an average rating of “Buy” and a consensus target price of $28.83.

Immunome Stock Up 8.1 %

Shares of IMNM stock opened at $13.73 on Monday. The company’s fifty day simple moving average is $12.23 and its two-hundred day simple moving average is $13.47. Immunome, Inc. has a 52 week low of $6.93 and a 52 week high of $30.96. The stock has a market cap of $857.03 million, a P/E ratio of -1.69 and a beta of 1.83.

Insider Transactions at Immunome

In other Immunome news, CEO Clay B. Siegall bought 66,057 shares of Immunome stock in a transaction dated Thursday, November 21st. The shares were purchased at an average cost of $9.54 per share, for a total transaction of $630,183.78. Following the acquisition, the chief executive officer now directly owns 485,693 shares in the company, valued at approximately $4,633,511.22. This represents a 15.74 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Max Rosett sold 14,380 shares of the company’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $16.01, for a total transaction of $230,223.80. Following the sale, the chief financial officer now owns 47,476 shares in the company, valued at $760,090.76. This represents a 23.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have bought 102,862 shares of company stock valued at $978,045. 8.60% of the stock is currently owned by insiders.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.